Group 1 - The Hong Kong IPO market has shown strong activity since the third quarter, with a significant increase in financing driven by a surge in companies filing for listings [1][2] - Deloitte's report predicts that the Hong Kong IPO market will maintain its position as the world's largest in terms of financing for the first three quarters of 2025, with total financing expected to reach between HKD 250 billion and HKD 280 billion [1][4] - The influx of overseas capital and regulatory encouragement for mainland companies to list in Hong Kong are key factors contributing to the growth of the IPO market [3][5] Group 2 - In the first three quarters of 2025, the Hong Kong IPO market is expected to see 66 new listings, raising HKD 182.3 billion, representing a 228% year-on-year increase in financing [2][4] - Notable companies such as CATL, Hengrui Medicine, and Sanhua Intelligent Control have raised over HKD 10 billion each through the "A+H" listing model, significantly boosting overall market financing [3] - The performance of these stocks in the secondary market has been strong, with cumulative price increases exceeding 70% since their listings [3] Group 3 - The fourth quarter of 2025 is anticipated to continue the strong momentum of the Hong Kong IPO market, supported by the Federal Reserve's potential interest rate cuts, which may lead to increased liquidity [4][5] - Deloitte estimates that there will be 80 new listings in the Hong Kong IPO market for the entire year of 2025, with total financing projected to be between HKD 250 billion and HKD 280 billion, a significant increase from previous forecasts [4] - The market is expected to see a diverse range of new listings, including those from pharmaceutical, specialized technology, and consumer sectors [4][5]

证券日报网讯9月23日晚间，恒瑞医药（600276）发布公告称，近日，公司子公司上海盛迪医药有限公 司收到国家药品监督管理局下发的《受理通知书》，公司阿得贝利单抗注射液新适应症的药品上市许可 申请获国家药监局受理。 ...

Core Viewpoint - Heng Rui Medicine (600276) has received acceptance for its drug listing application for SHR7280 tablets from the National Medical Products Administration [1] Group 1 - The company announced on the evening of September 23 that it has received the acceptance notice for its drug listing application [1]

Group 1: Company Announcements - Ganli Pharmaceutical signed a technology transfer and supply agreement with FZ and BIOMM, with a total supply framework agreement amount expected to be no less than 3 billion RMB [1] - Upwind New Materials completed the transfer of 121 million shares, changing its controlling shareholder to Zhiyuan Hengyue, associated with Zhiyuan Robotics [2] - Poly Developments plans to publicly issue corporate bonds not exceeding 15 billion RMB for various purposes including debt repayment and project construction [3] Group 2: Shareholder Actions - Lenovo Holdings reduced its stake in Lakala by 8.0781 million shares, decreasing its ownership from 25.00% to 23.97% [4] - Fenghuo Communication plans to repurchase shares with a budget between 75 million and 150 million RMB, with a maximum repurchase price of 40.53 RMB per share [5] - Hualing Cable intends to acquire control of San Bamboo Intelligent for no more than 270 million RMB to enhance its capabilities in robotics and high-frequency transmission [6] Group 3: Market Developments - Guiguang Network clarified that rumors regarding major collaborations with Huawei Cloud and restructuring with state-owned enterprises are untrue [7] - Dongshan Precision is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international presence [8] - Wolong Nuclear Materials' subsidiary plans to invest up to 1 billion RMB in a new materials project in Suzhou [9] Group 4: Other Corporate Activities - Chao Xun Communication's management completed their share reduction plan, with specific shares sold by board members [10] - Various companies are involved in significant project bids and collaborations, including China Electric Research and others [15]

Core Viewpoint - Heng Rui Medicine has received acceptance for its drug application SHR7280 from the National Medical Products Administration, indicating progress in its development for assisted reproductive technology [1] Group 1: Drug Information - SHR7280 is an oral small molecule GnRH receptor antagonist designed to prevent early luteinizing hormone (LH) peaks in patients undergoing controlled ovarian stimulation [1] - The drug works by blocking the binding of endogenous GnRH to GnRH receptors, thereby inhibiting the synthesis and release of LH and other gonadotropins [1] Group 2: Application and Indication - The intended use of SHR7280 is in controlled ovarian hyperstimulation treatment within assisted reproductive technology [1]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月23日，恒瑞医药发布公告称，公司子公司成都盛迪医 药有限公司收到国家药品监督管理局核准签发关于HRS—3095片的《药物临床试验批准通知书》，将于 近期开展临床试验。公告显示，HRS—3095片是恒瑞医药自主研发的靶向免疫细胞的小分子化合物，对 过敏性疾病起到良好的治疗效果。 ...

公告显示，阿得贝利单抗注射液是恒瑞医药自主研发的人源化抗PD—L1单克隆抗体，能通过特异性结 合PD—L1分子从而阻断导致肿瘤免疫耐受的PD—1/PD—L1通路，重新激活免疫系统的抗肿瘤活性，从 而达到治疗肿瘤的目的。 北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月23日，恒瑞医药发布公告称，公司子公司上海盛迪医 药有限公司收到国家药品监督管理局下发的《受理通知书》，阿得贝利单抗注射液新适应症的药品上市 许可申请获国家药监局受理。 ...

香港联交所最新资料显示，9月19日，The Capital Group Companies,Inc.增持恒瑞医药（600276） (01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58万 股，最新持股比例为7.65%。 ...

智通财经APP获悉，香港联交所最新资料显示，9月19日，The Capital Group Companies, Inc.增持恒瑞医 药(01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58 万股，最新持股比例为7.65%。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...